acromegaly
ACROMEGALY
Acromegaly is a chronic, slowly developing disease with progressive disfigurement and disability. An early diagnosis is difficult as most signs and symptoms are due to long-standing overproduction of growth hormone &/or insulin-like growth factor (IGF-I) causing metabolic, endocrine and morphological changes.
Surgical intervention is the first-line of treatment for almost all patients with acromegaly unless there are contraindications or the patient refuses to undergo the procedure.

Surgical Intervention

Surgical intervention is the 1st-line of treatment for almost all patients with acromegaly unless there are contraindications or the patient refuses to undergo the procedure

Patients not Eligible for Surgical Treatment

  • Medically unstable condition
  • Patients with airway difficulties and are at high risk for anesthetic complications
  • Major systemic manifestations of acromegaly:
    • Cardiomyopathy
    • Severe hypertension
    • Uncontrolled diabetes mellitus

Goals of Surgical Treatment:

  • To decrease tumor burden, and cure if possible, with preservation of normal pituitary function
  • To reduce mass effect of macroadenomas on remaining normal pituitary gland tissues, the optic chiasm or nerves, and other surrounding structures
  • To rapidly lower or reduce growth hormone and insulin-like growth factor-I levels, control or prevent progression of disease, and relieve associated comorbidities

Transsphenoidal Surgery

  • Treatment of choice for all patient with microadenomas and or all patients who have macroadenomas with associated mass effect
    • In patients with macroadenomas without mass effects, and low likelihood of surgical cure, surgical debulking may improve response to subsequent medical therapy
    • Primary medical therapy alone has also been advocated for those with macroadenomas not likely to be cured by surgery
  • Transnasal endoscopic procedures have shown improved patients satisfaction and shorter hospital stay compared with traditional sublabial procedures, without compromising surgical success
  • In noninvasive macroadenomas, biochemical control with normalization of insulin-like growth factor-I occurs in 40-68% of the patients
  • In intrasellar microadenomas, surgery provides biochemical control and normalization of insulin-like growth factor-I in 75-95% of patients
  • Surgery requires expertise to achieve control rates
  • Some clinicians have found benefits with the use of somatostatin receptor ligands (SRL) prior to surgery
    • Some have claimed pretreatment with SRLs have improved normalization of growth hormone and insulin-like growth factor-I after surgery and shorten the duration of hospital stay
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
03 Sep 2018
Dietary nicotinamide riboside (NR) supplementation in 2,000-mg doses daily over a 12-week period is safe, a recent study has shown. However, it does not improve insulin sensitivity and whole-body glucose metabolism in obese, insulin-resistant men.
01 Oct 2015
Type 1 diabetes mellitus occurrence among the paediatric population is fast rising, especially among 5-9-year olds, based on a 26-year observational study.
07 Apr 2016
Radha Chitale spoke with Dr. Kim A. Williams, Sr., who served as the 2015-2016 president of the American College of Cardiology, during the organization's annual meeting in Chicago, Illinois, US as he reflected on his term and discussed what's exciting in cardiology. 
Dr. Joseph Delano Fule Robles, 25 Jul 2018

Prior to considering pharmacotherapy or surgery, weight reduction can be achieved through dietary modification and management of meal habits, sleep hours and stress.